

# Andrew Rawstron

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7563330/publications.pdf>

Version: 2024-02-01

110  
papers

8,617  
citations

71102

41  
h-index

43889

91  
g-index

112  
all docs

112  
docs citations

112  
times ranked

6510  
citing authors

#	ARTICLE	IF	CITATIONS
1	Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2008, 359, 575-583.	27.0	518
2	Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma. JAMA Oncology, 2017, 3, 28.	7.1	405
3	Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival. Journal of Clinical Oncology, 2005, 23, 2971-2979.	1.6	380
4	Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study. Journal of Clinical Oncology, 2013, 31, 2540-2547.	1.6	372
5	Diagnostic criteria for monoclonal B-cell lymphocytosis. British Journal of Haematology, 2005, 130, 325-332.	2.5	360
6	International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia, 2007, 21, 956-964.	7.2	351
7	Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood, 2002, 100, 635-639.	1.4	305
8	Human peripheral blood B-cell compartments: A crossroad in B-cell traffic. Cytometry Part B - Clinical Cytometry, 2010, 78B, S47-60.	1.5	258
9	Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood, 2001, 98, 29-35.	1.4	249
10	Response assessment in Waldenström macroglobulinaemia: update from the 14th International Workshop. British Journal of Haematology, 2013, 160, 171-176.	2.5	226
11	Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood, 2002, 100, 2289-2290.	1.4	207
12	A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia, 2016, 30, 929-936.	7.2	200
13	Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. Journal of Clinical Oncology, 2019, 37, 2722-2729.	1.6	197
14	Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood, 2002, 100, 3095-3100.	1.4	194
15	Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia, 2010, 24, 512-520.	7.2	193
16	Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis and Rheumatism, 2008, 58, 2993-2999.	6.7	187
17	Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood, 2002, 99, 2245-2247.	1.4	184
18	Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia, 2013, 27, 142-149.	7.2	176

#	ARTICLE	IF	CITATIONS
19	Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. <i>Blood</i> , 2004, 104, 948-955.	1.4	175
20	Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. <i>British Journal of Haematology</i> , 1997, 97, 46-55.	2.5	165
21	Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. <i>Blood</i> , 2015, 125, 1932-1935.	1.4	163
22	Alemtuzumab in Combination With Methyprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 1647-1655.	1.6	152
23	Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 31-39.	1.5	144
24	Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 121-128.	1.5	133
25	In Vitro Generation of Long-lived Human Plasma Cells. <i>Journal of Immunology</i> , 2012, 189, 5773-5785.	0.8	111
26	Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1236-1241.	1.6	109
27	Minimal residual disease is an independent predictor for 10-year survival in CLL. <i>Blood</i> , 2016, 128, 2770-2773.	1.4	106
28	The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. <i>British Journal of Haematology</i> , 2001, 112, 814-819.	2.5	103
29	Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S19-23.	1.5	86
30	Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. <i>Blood</i> , 2013, 121, 4521-4528.	1.4	81
31	The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. <i>Blood</i> , 2000, 96, 3880-3886.	1.4	78
32	Overview of monoclonal B-cell lymphocytosis. <i>British Journal of Haematology</i> , 2007, 139, 701-708.	2.5	72
33	IgM myeloma: a rare entity characterized by a CD20 <sup>+</sup> CD56 <sup>+</sup> CD117 <sup>+</sup> immunophenotype and the t(11;14). <i>British Journal of Haematology</i> , 2008, 140, 547-551.	2.5	66
34	The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. <i>British Journal of Haematology</i> , 1999, 107, 148-153.	2.5	64
35	Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. <i>Blood</i> , 2004, 103, 2027-2031.	1.4	64
36	Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium. <i>American Journal of Hematology</i> , 2014, 89, 1159-1160.	4.1	52

#	ARTICLE	IF	CITATIONS
37	Assessment of Bone Marrow Response in Waldenström's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 53-55.	1.4	48
38	Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood, 2014, 124, 1296-1299.	1.4	48
39	Assessment of IgH PCR strategies in multiple myeloma.. Journal of Clinical Pathology, 1996, 49, 672-675.	2.0	44
40	Monoclonal B-cell lymphocytosis. Hematology American Society of Hematology Education Program, 2009, 2009, 430-439.	2.5	44
41	Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia, 2006, 20, 2102-2110.	7.2	43
42	Inherited genetic susceptibility to monoclonal B-cell lymphocytosis. Blood, 2010, 116, 5957-5960.	1.4	42
43	Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen. Haematologica, 2016, 101, e69-e71.	3.5	41
44	Prevalence of monoclonal B-cell lymphocytosis: A systematic review. Cytometry Part B - Clinical Cytometry, 2010, 78B, S10-8.	1.5	40
45	Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition. Journal of Immunology, 2017, 198, 4618-4628.	0.8	40
46	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia, 2021, 35, 3059-3072.	7.2	40
47	A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma. Leukemia, 2007, 21, 2046-2049.	7.2	39
48	A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. British Journal of Haematology, 2011, 152, 570-578.	2.5	38
49	B-cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle. British Journal of Haematology, 2007, 139, 600-604.	2.5	35
50	Assessment of minimal residual disease in myeloma and the need for a consensus approach. Cytometry Part B - Clinical Cytometry, 2016, 90, 21-25.	1.5	35
51	Monoclonal B-cell lymphocytosis (MBL) in CLL families: substantial increase in relative risk for young adults. Leukemia, 2006, 20, 728-729.	7.2	33
52	Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. British Journal of Haematology, 2013, 160, 640-648.	2.5	33
53	The biological and clinical relationship between CD5+23+monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia. British Journal of Haematology, 2007, 139, 724-729.	2.5	32
54	Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials, 2017, 18, 387.	1.6	31

#	ARTICLE	IF	CITATIONS
55	CD52 Expression in Waldenström's Macroglobulinemia: Implications for Alemtuzumab Therapy and Response Assessment. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 278-281.	2.1	29
56	Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. <i>Journal of Clinical Oncology</i> , 2022, 40, 2889-2900.	1.6	29
57	Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. <i>Leukemia</i> , 2017, 31, 2085-2093.	7.2	27
58	Isotype class switching and the pathogenesis of multiple myeloma. <i>Hematological Oncology</i> , 2002, 20, 75-85.	1.7	25
59	Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal B-cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S42-6.	1.5	25
60	Immunophenotyping of Plasma Cells. <i>Current Protocols in Cytometry</i> , 2006, 36, Unit6.23.	3.7	24
61	Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. <i>Leukemia</i> , 2017, 31, 2416-2425.	7.2	24
62	Clinical and diagnostic implications of monoclonal B-cell lymphocytosis. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 61-69.	1.7	20
63	Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 54-60.	1.5	20
64	Clonal lymphocytes in persons without known chronic lymphocytic leukemia (CLL): implications of recent findings in family members of CLL patients. <i>Seminars in Hematology</i> , 2004, 41, 192-200.	3.4	19
65	Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice. <i>British Journal of Haematology</i> , 2005, 128, 732-733.	2.5	19
66	Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments. <i>Leukemia</i> , 2018, 32, 1307-1316.	7.2	19
67	Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia: Should This Be the Goal of Treatment?. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 35-44.	2.3	18
68	Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL. <i>Blood</i> , 2020, 135, 411-428.	1.4	17
69	Monoclonal B Cell Lymphocytosis—What Does It Really Mean?. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 52-59.	2.3	16
70	Minimal residual disease assessment in chronic lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 499-512.	1.7	15
71	Occult B-cell lymphoproliferative disorders. <i>Histopathology</i> , 2011, 58, 81-89.	2.9	14
72	Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. <i>Health Technology Assessment</i> , 2017, 21, 1-374.	2.8	14

#	ARTICLE	IF	CITATIONS
73	Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from <scp>NCRN CLL</scp>207: a phase <scp>II</scp> trial assessing alemtuzumab consolidation. British Journal of Haematology, 2017, 176, 573-582.	2.5	13
74	Immunophenotypic and DNA Genotypic Analysis of T-Cell and NK-Cell Subpopulations in Patients with B-Cell Chronic Lymphocytic Leukaemia (B-CLL). Leukemia and Lymphoma, 1995, 16, 307-318.	1.3	12
75	FICTION-TSA analysis of the B-cell compartment in myeloma shows no significant expansion of myeloma precursor cells. British Journal of Haematology, 1999, 106, 40-46.	2.5	12
76	Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study. Lancet Haematology, 2017, 4, e334-e340.	4.6	12
77	Telomere length predicts for outcome to FCR chemotherapy in CLL. Leukemia, 2019, 33, 1953-1963.	7.2	12
78	Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience. British Journal of Haematology, 2007, 139, 845-848.	2.5	11
79	Immunoglobulin M Concentration in Waldenström Macroglobulinemia: Correlation With Bone Marrow B Cells and Plasma Cells. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 211-213.	0.4	11
80	Prevalence and characteristics of monoclonal B-cell lymphocytosis (MBL) in healthy individuals and the relationship with clinical disease. Journal of Biological Regulators and Homeostatic Agents, 2004, 18, 155-60.	0.7	11
81	Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells. Oncogenesis, 2019, 8, 32.	4.9	10
82	Controversies surrounding the clonogenic origin of multiple myeloma. British Journal of Haematology, 2000, 110, 240-241.	2.5	10
83	Assessing minimal residual disease in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports, 2008, 3, 47-53.	2.3	9
84	Final Report of the UKCLLO2 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).. Blood, 2006, 108, 34-34.	1.4	9
85	CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy. Haematologica, 2006, 91, 1577-8.	3.5	9
86	Commentary: Comparison of current flow cytometry methods for monoclonal B cell lymphocytosis detection. Cytometry Part B - Clinical Cytometry, 2010, 78B, S4-9.	1.5	7
87	Circulating primitive stem cells in paroxysmal nocturnal hemoglobinuria (PNH) are predominantly normal in phenotype but granulocyte colony-stimulating factor treatment mobilizes mainly PNH stem cells. Blood, 1998, 91, 4504-8.	1.4	7
88	Is MRD eradication a desirable goal in CLL?. Best Practice and Research in Clinical Haematology, 2010, 23, 97-107.	1.7	6
89	Monoclonal B-Cell Lymphocytosis (MBL) and CLL Show Intracлонаl Variation: Cases Classified as "Unmutated" Have the Greatest Clonal Diversity.. Blood, 2006, 108, 30-30.	1.4	6
90	The bone marrow microenvironment influences the differential chemokine receptor expression of normal and neoplastic plasma cells. Blood, 2005, 105, 4895-4896.	1.4	5

#	ARTICLE	IF	CITATIONS
91	Demonstration of a Germinal Center Immunophenotype in Lymphomas by Immunocytochemistry and Flow Cytometry. , 2005, 115, 065-092.		5
92	GA101 (obinutuzumab) monoclonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial. Trials, 2017, 18, 353.	1.6	5
93	Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort. BMJ Open, 2021, 11, e041296.	1.9	5
94	Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Therapeutic Endpoint for Relapsed CLL.. Blood, 2007, 110, 3114-3114.	1.4	5
95	Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. Leukemia, 2022, 36, 271-274.	7.2	4
96	International Standardized Approach to Molecular and Flow Cytometric Residual Disease Monitoring in CLL.. Blood, 2004, 104, 15-15.	1.4	4
97	Monoclonal B-cell lymphocytosis: Good news for patients and CLL investigators. Leukemia and Lymphoma, 2007, 48, 1057-1058.	1.3	3
98	Laboratory Diagnosis of Chronic Lymphocytic Leukaemia. Hematologic Malignancies, 2019, , 21-35.	0.2	3
99	Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group). Blood, 2010, 116, 922-922.	1.4	3
100	Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with &gt;1 Year Prior Ibrutinib Exposure. Blood, 2020, 136, 27-28.	1.4	2
101	Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. Trials, 2016, 17, 456.	1.6	1
102	Highly selective <sc>SYK</sc> inhibitor, <sc>GSK</sc>143, abrogates survival signals in chronic lymphocytic leukaemia. British Journal of Haematology, 2018, 182, 927-930.	2.5	1
103	COSMIC, chemotherapy plus ofatumumab at standard or megaâ€dose in chronic lymphocytic leukaemia, a phase II randomised study. British Journal of Haematology, 2021, 194, 646-650.	2.5	1
104	The Prognostic Significance of Phenotypically â€Normalâ€™ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma. Blood, 2014, 124, 2073-2073.	1.4	1
105	Minimal residual disease detection in myeloma: no more molecular remissions?. Haematologica, 2005, 90, 1300B.	3.5	1
106	P245â€Identifying predictors of short-term response to rituximab in extra-glandular primary Sjogrenâ€™s Syndrome. Rheumatology, 2022, 61, .	1.9	1
107	Histopathology, Morphology and Immunophenotyping of CLL. , 2013, , 71-89.		0
108	Reply to M. Roschewski et al. Journal of Clinical Oncology, 2014, 32, 476-477.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Etiology of CLL. , 2008, , 69-89.		0
110	OA13â€fComprehensive genetic and functional analyses of Fc gamma receptors explain response to rituximab therapy for autoimmune rheumatic diseases. Rheumatology, 2022, 61, .	1.9	0